Alzheimer’s Disease as Type 3 Diabetes: Understanding the Link and Implications
Alzheimer’s disease (AD) and type 2 diabetes mellitus (T2DM) are two prevalent conditions that present considerable public health issue in
A forum for researchers, students and applicants in the field of cyclodextrin technology
Alzheimer’s disease (AD) and type 2 diabetes mellitus (T2DM) are two prevalent conditions that present considerable public health issue in
On 15 August, 2024 Douglas Kelley, professor of mechanical engineering at the University of Rochester and his co-workers published that
Niemann-Pick disease type C (NPC) is a rare, fatal, pan-ethnic, autosomal recessive lysosomal storage disease characterized by progressive major organ
Neurodegeneration is characterized by progressive, disabling, and incurable neurological disorders with the massive loss of specific neurons. As one of
Globally, more than 67 million people are living with the effects of ischemic stroke. Importantly, many stroke survivors develop a
Mallinckrodt Pharmaceuticals has reached an agreement to divest and transfer the Investigational New Drug (IND) application for experimental drug adrabetadex
Therapies targeting neurological conditions such as Alzheimer’s or Parkinson’s diseases are hampered by the presence of the blood-brain barrier (BBB).
CycloLab Cyclodextrin R&D Ltd. proudly announces winning of a national grant about the development of cyclodextrin-dervatives for autophagy-associated neurodegenerative diseases.
Cyclo Therapeutics reported the publication of an international patent application for the treatment of Alzheimer’s disease with HPBCD.
“World Congress on Neuroscience and Brain Disorders” is scheduled to be held from March 30-31, 2020 in Osaka, Japan. The